Indeed, in an early study, no significant difference in the treatment effect, as measured by ADHD rating scale end point values, was observed between CYP2D6 EMs and PMs, in any tested cohorts [37]. Here, CYP2D6 is linked to attention deficit-hyperactivity disorder.